Your New Heart Could Be Made in China
August 12, 2019
(Bloomberg) – Recently, a Chinese startup named Qihan Biotech raised $20 million to develop replacement organs for humans. The smallish deal would hardly have rated a headline, except for the fact that the Hangzhou-based gene-editing company is aiming to grow those organs in pigs and other animals. If successful, such transplants could well transform medicine. And, thanks to a unique confluence of need, money, timing and culture, China is poised to lead the way in developing them.